Amlodipine Use in Patients with Crohn's Disease

Safety Profile and Clinical Use

Amlodipine is a dihydropyridine calcium channel blocker with an established safety profile across diverse patient populations, including those with complex comorbidities, and is recommended as a first-line antihypertensive agent by major cardiovascular guidelines, such as the American Heart Association and European Society of Cardiology 1, 2, 3
The American Heart Association and European Society of Cardiology recommend long-acting amlodipine as a first-line calcium channel blocker for effective blood pressure control in patients with hypertension, including those with Crohn's disease 1
Amlodipine can be safely combined with ACE inhibitors or angiotensin receptor blockers without dangerous drug interactions, according to clinical guidelines 4
Amlodipine is safe in patients with renal dysfunction, which may be relevant given potential renal complications in Crohn's disease, as supported by the American Journal of Kidney Diseases 5

Amlodipine has minimal effects on cardiac contractility, atrioventricular conduction, and heart rate, making it well-tolerated even in patients with multiple comorbidities, as reported by Praxis Medical Insights 4

No special dose adjustments are required based on the presence of Crohn's disease, and the primary side effect to monitor is peripheral edema, which occurs in a minority of patients and is related to the vasodilatory action of the drug, as noted by Praxis Medical Insights 4